Clinical and economic evaluation of tapentadol extended release and oxycodone/naloxone extended release in comparison with controlled release oxycodone in musculoskeletal pain

References

• Breivik H, Collett B, Ventafridda V, et al. Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment. Eur J Pain 2006;10:287-33
   PubMed Web of Science ®Google Scholar
• Langley P. The prevalence, correlates and treatment of pain in the European Union. Curr Med Res Opin 2011;27:463-80
   PubMed Web of Science ®Google Scholar
• Langley P, Müller-Schwefe G, Nicolaou A, et al. The impact of pain on labor force participation, absenteeism and presenteeism in the European Union. J Med Econ 2010;13:662-72
   PubMedGoogle Scholar
• Merskey H, Bogduk N, eds. Classification of Chronic Pain: Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms, 2nd edn. Seattle, WA: IASP Press, 1994:1-16
   Google Scholar
• Pergolizzi J, Ahlbeck K, Aldington D, et al. The chronic pain conundrum: should we CHANGE from relying on past history to assessing prognostic factors? Curr Med Res Opin 2012;28:249-56
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Berti M. Change pain: changing the approach to chronic pain. Minerva Med 2011;102:289-307
   PubMed Web of Science ®Google Scholar
• Ambrosio F, Finco G, Mattia C, et al. SIAARTI recommendations for chronic non cancer pain. Minerva Anestesiol 2006;72:859-80
   PubMed Web of Science ®Google Scholar
• Trescot AM, Helm S, Hansen H, et al. Opioids in the management of chronic non-cancer pain: an update of American Society of the Interventional Pain Physicians’ (ASIPP) Guidelines. Pain Physician 2008;11(2 Suppl):S5-62
   PubMed Web of Science ®Google Scholar
• Coluzzi F, Rocco A, Mandatori I, et al. Non-analgesic effects of opioids: opioid-induced nausea and vomiting: mechanisms and strategies for their limitation. Curr Pharmaceut Des 2012;18:6043-52
   PubMed Web of Science ®Google Scholar
• Holzer P. Non-analgesic effects of opioids: management of opioid-induced constipation by peripheral opioid receptor antagonists: prevention or withdrawal? Curr Pharm Des 2012;18:6010-20
   PubMed Web of Science ®Google Scholar
• Pergolizzi JV, Raffa RB, Pergolizzi JS, et al. Non-analgesic effects of opioids: Factors relevant to opioid abuse and abuse-deterrent formulations. Curr Pharm Des 2012;18:6109-15
   PubMed Web of Science ®Google Scholar
• Brock C, Olesen SS, Olesen AE, et al. Opioid-induced bowel dysfunction: pathophysiology and management. Drugs 2012;72:1847-65
   PubMed Web of Science ®Google Scholar
• Buynak R, Shapiro DY, Okamoto A, et al. Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled phase III study. Expert Opin Pharmacother 2010;11:1787-804
   PubMed Web of Science ®Google Scholar
• Afilalo M, Etropolski MS, Kuperwasser B, et al. Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig 2010;30:489-505
   PubMed Web of Science ®Google Scholar
• Wild JE, Grond S, Kuperwasser B, et al. Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract 2010;10:416-27
   PubMed Web of Science ®Google Scholar
• Lange B, Kuperwasser B, Okamoto A, et al. Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther 2010;27:381-99
   PubMed Web of Science ®Google Scholar
• Löwenstein O, Leyendecker P, Hopp M, et al. Combined prolonged-release oxycodone and naloxone improves bowel function in patients receiving opioids for moderate-to-severe non-malignant chronic pain: a randomised controlled trial. Expert Opin Pharmacother 2009;10:531-43
   PubMed Web of Science ®Google Scholar
• Simpson K, Leyendecker P, Hopp M, et al. Fixed-ratio combination oxycodone/naloxone compared with oxycodone alone for the relief of opioid-induced constipation in moderate-to-severe noncancer pain. Curr Med Res Opin 2008;24:3503-12
   PubMed Web of Science ®Google Scholar
• Vondrackova D, Leyendecker P, Meissner W, et al. Analgesic efficacy and safety of oxycodone in combination with naloxone as prolonged release tablets in patients with moderate to severe chronic pain. J Pain 2008;9:1144-54
   PubMed Web of Science ®Google Scholar
• Meissner W, Leyendecker P, Mueller-Lissner S, et al. A randomised controlled trial with prolonged-release oral oxycodone and naloxone to prevent and reverse opioid-induced constipation. Eur J Pain 2009;13:56-64
   PubMed Web of Science ®Google Scholar
• Maniadakis N, Gray A. The economic burden of back pain in the UK. Pain 2000;84:95-103
   PubMed Web of Science ®Google Scholar
• Camilleri M. Opioid-induced constipation: challenges and therapeutic opportunities. Am J Gastroenterol 2011;106:835-42
   PubMed Web of Science ®Google Scholar
• Hjalte F, Berggren AC, Bergendahl H, et al. The direct and indirect costs of opioid-induced constipation. J Pain Symptom Manage 2010;40:696-703
   PubMed Web of Science ®Google Scholar
• Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009;338:b1147
   PubMed Web of Science ®Google Scholar
• Ioannidis JP. Indirect comparisons: the mesh and mess of clinical trials. Lancet 2006;368:1470-2
   PubMed Web of Science ®Google Scholar
• Ikenberg R, Hertel N, Moore RA, et al. Cost-effectiveness of tapentadol prolonged release compared with oxycodone controlled release in the UK in patients with severe non-malignant chronic pain who failed 1st line treatment with morphine. J Med Econ 2012;15:724-36
   PubMedGoogle Scholar
• Merchant S, Noe L, Howe A, et al. Budget impact analysis of tapentadol extended release for the treatment of moderate to severe chronic noncancer pain. Clin Therapeut 2013;35:659-72
   Google Scholar
• [Recognition and first update of the maximum reimbursement rates for medical practice]. Official Gazette of the Italian Republic, n. 289, 13th December 2006
   Google Scholar
• Obradovic M, Ikenberg R, Hertel N, et al. Cost-effectiveness of tapentadol in severe chronic pain in Spain: a cost analysis of data from RCTs. Clin Ther 2012;34:926-43
   PubMed Web of Science ®Google Scholar
• Dunlop W, Uhl R, Khan I, et al. Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced constipation: a UK cost–utility analysis. J Med Econ 2012;15:564-75
   PubMedGoogle Scholar
• SMC advice > 541 09 oxycodone/naloxone (Targinact) > Briefing Note. Available at: www.scottishmedicines.org.uk [Last accessed January 2014]
   Google Scholar
• Neil N, Merchant S, Provenzano D, et al. Clinical simulation model of long-acting opioids for the treatment of chronic non-cancer pain in the United States. J Med Econ 2013;16:307-17
   PubMedGoogle Scholar